Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
Stock Information for Medicenna Therapeutics Corp.
Loading
Please wait while we load your information from QuoteMedia.